Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

NCT04215146 is registered in ClinicalTrials.gov with Oncolytics Biotech as lead sponsor.

NCT NCT04215146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04215146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
Lead sponsor
Oncolytics Biotech
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 10, 2020
Completion date
June 30, 2025
Enrollment
48 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer metastatic